Joshua Matovu

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study

Allan Buzibye, Kara Wools‐Kaloustian, Adeniyi Olagunju, Ellon Twinomuhwezi et autres

BACKGROUND: We investigated the association between CYP2B6 polymorphisms and efavirenz drug resistance among women living with HIV who started on antiretroviral therapy during pregnancy and with high viremia during post-partum. METHODS: This was a cross-sectional study of women with viral loads greater …

Ouganda, us, gb (code pays fourni par la source)

Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda

Denis Omali, Allan Buzibye, Richard Kwizera, Pauline Byakika‐Kibwika et autres

Background: Research and clinical use of clinical pharmacology laboratories are limited in low- and middle-income countries. We describe our experience in building and sustaining laboratory capacity for clinical pharmacology at the Infectious Diseases Institute, Kampala, Uganda. Intervention: Existing laboratory infrastructure was repurposed, …

Ouganda, ch, gb, us, ie (code pays fourni par la source)

A portable magnetofluidic platform for detecting sexually transmitted infections and antimicrobial susceptibility

Alexander Y. Trick, Johan H. Melendez, Fan‐En Chen, Liben Chen et autres

detection and 100% concordance with culture results for ciprofloxacin resistance. This study paves the way for delivering accessible PCR diagnostics for rapidly detecting STIs at the point of care, helping to guide treatment decisions and combat the rise of antimicrobial resistant pathogens.

us, Ouganda (code pays fourni par la source)

Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.

Allan Buzibye, Kara Wools‐Kaloustian, Adeniyi Olagunju, Ellon Twinomuhwezi et autres

Ouganda, us, Nigéria, gb (code pays fourni par la source)

MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection

Sarah A.E. Rupprechter, Derek J. Sloan, Wilna Oosthuyzen, Till T. Bachmann et autres

AIMS: Patients on antituberculosis (anti-TB) therapy are at risk of drug-induced liver injury (DILI). MicroRNA-122 (miR-122) and cytokeratin-18 (K18) are DILI biomarkers. To explore their utility in this global context, circulating miR-122 and K18 were measured in UK and Ugandan populations on …

gb, Ouganda (code pays fourni par la source)

MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for tuberculosis

Sarah A.E. Rupprechter, Derek J. Sloan, Wilna Oosthuyzen, Till T. Bachmann et autres

Aim Patients on anti-tuberculosis (anti-TB) therapy are at risk of drug-induced liver injury (DILI). MicroRNA-122 (miR-122) and cytokeratin-18 (K18) are exploratory DILI biomarkers. To explore their utility in this global context, circulating miR-122 and K18 concentrations were measured in UK and Ugandan …

gb, Ouganda (code pays fourni par la source)

Cytokeratin-18 has potential as a biomarker of drug-induced liver injury in European and African patients on treatment for tuberculosis

Sarah A.E. Rupprechter, Derek J. Sloan, Wilna Oosthuyzen, Till T. Bachmann et autres

Abstract Patients on anti-tuberculosis (anti-TB) therapy are at risk of developing drug-induced liver injury (DILI). Cytokeratin-18 (K18) is an exploratory DILI biomarker that has been developed predominately in Caucasian populations and not African populations in whom TB is common. Our aim was …

gb, us, Ouganda (code pays fourni par la source)

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART

Megan Neary, Catherine A. Chappell, Kimberly K. Scarsi, Shadia Nakalema et autres

BACKGROUND: We previously demonstrated that etonogestrel concentrations were 82% lower in women using etonogestrel contraceptive implants plus efavirenz-based ART compared with women not receiving ART. OBJECTIVES: To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes …

gb, us, Ouganda (code pays fourni par la source)

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

JA Thompson, Cissy Kityo, David Dunn, Anne Hoppé et autres

BACKGROUND: Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of treatment failure. The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear. METHODS: We retrospectively tested VL in 2164 stored …

gb, Ouganda, ca, Zimbabwe, Malawi, es, sg (code pays fourni par la source)

CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.

MG Neary, Catherine A. Chappell, Kimberly K. Scarsi, Shadia Nakalema et autres

Delayed Sputum Culture Conversion in Tuberculosis–Human Immunodeficiency Virus–Coinfected Patients With Low Isoniazid and Rifampicin Concentrations

Christine Sekaggya‐Wiltshire, Amrei von Braun, Mohammed Lamorde, Bruno Ledergerber et autres

Background: The relationship between concentrations of antituberculosis drugs, sputum culture conversion, and treatment outcome remains unclear. We sought to determine the association between antituberculosis drug concentrations and sputum conversion among patients coinfected with tuberculosis and human immunodeficiency virus (HIV) and receiving first-line …

Ouganda, ch, au, Afrique du Sud, us (code pays fourni par la source)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, JA Thompson, Cissy Kityo, Anne Hoppé et autres

BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the …

Zimbabwe, gb, Ouganda, Malawi, Kenya, Zambie, sg (code pays fourni par la source)